title: Relation between serum anti-p53 antibodies and microvessel density in bladder cancer patients.
abstract: BACKGROUND
  Etiology of serum anti-p53 antibodies in bladder cancer patients is still unknown. In this study we evaluated the relationship between serum anti-p53 antibodies and microvessel density in bladder cancer patients.
  
  
  METHODS
  Seventy-six patients with transitional cell carcinoma of the urinary bladder were assessed prospectively (18 Ta, 30 T1, 28 T2>or =). Serum anti-p53 antibodies were detected by enzyme-linked immunosorbent assay. Tumor p53 overexpression was assessed by immunohistochemical staining. Vessels were stained immunohistochemically using an antibody against platelet endothelial cell-adhesion molecule CD31. Spearman correlation test and t test were used for statistical analysis.
  
  
  RESULTS
  Serum anti-p53 antibodies were positive in 25 (60%) of 41 tumor p53-positive patients. While the mean (SD, range) microvessel density was found to be 43 (7.59, 8-99) in patients who had positive serum anti-p53 antibodies, it was found to be 23 (4.53, 6-98) in patients who had negative serum anti-p53 antibodies. There was a good correlation between serum anti-p53 antibodies and microvessel density (p<0.05). No correlation was found between tumor p53 expression and microvessel density (p>0.05).
  
  
  CONCLUSIONS
  We found that there is a significant correlation between the microvessel density and serum anti-p53 antibodies. This result may show the role of angiogenesis in the etiology of serum anti-p53 antibodies in bladder cancer patients.
authors.affiliation: 2nd Urology Clinic, Sisli Etfal Training and Research Hospital, Istanbul University, Istanbul, Turkey. eyupg@superonline.com
authors.forename: Eyup
authors.initials: E
authors.lastname: Gumus
authors.forename: Sibel
authors.initials: S
authors.lastname: Erdamar
authors.forename: Gulderen
authors.initials: G
authors.lastname: Demirel
authors.forename: Kaya
authors.initials: K
authors.lastname: Horasanli
authors.forename: Gökhan
authors.initials: G
authors.lastname: Ozmen
authors.forename: Cengiz
authors.initials: C
authors.lastname: Miroglu
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000502:physiology*; D002295:Carcinoma, Transitional Cell / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D016159:Tumor Suppressor Protein p53 / Q000502:physiology*; D001743:Urinary Bladder / Q000098:blood supply; D001749:Urinary Bladder Neoplasms / Q000503:physiopathology*
chemical_list: D000906:Antibodies; D016159:Tumor Suppressor Protein p53